Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (3)
  • Open Access


    A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer

    Jiayi Huang1, Xue Bai1, Xiaofeng Xie1, Liping Chen1, Xiaofeng Lan1, Qiuyi Zhang1, Lin Song1, Pengjiao Hong2,3, Caiwen Du1,*

    Oncologie, Vol.24, No.1, pp. 131-145, 2022, DOI:10.32604/oncologie.2022.019881

    Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese… More >

  • Open Access


    Prognostic tumor microenvironment gene and the relationship with immune infiltration characteristics in metastatic breast cancer


    BIOCELL, Vol.46, No.5, pp. 1215-1243, 2022, DOI:10.32604/biocell.2022.018221

    Abstract The aim of this study was to reveal genes associated with breast cancer metastasis, to investigate their intrinsic relationship with immune cell infiltration in the tumor microenvironment, and to screen for prognostic biomarkers. Gene expression data of breast cancer patients and their metastases were downloaded from the GEO, TCGA database. R language package was used to screen for differentially expressed genes, enrichment analysis of genes, PPI network construction, and also to elucidate key genes for diagnostic and prognostic survival. Spearman’s r correlation was used to analyze the correlation between key genes and infiltrating immune cells.… More >

  • Open Access


    Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population

    Keiichi Kontani1,*, Kana Kuraishi1, Shin-ichiro Hashimoto1, Shoko Norimura2, Nozomi Hashimoto1, Masahiro Ohtani3, Naomi Fujiwara-Honjo4, Manabu Date5, Koji Teramoto6, Hiroyasu Yokomise1

    Oncologie, Vol.23, No.2, pp. 229-239, 2021, DOI:10.32604/Oncologie.2021.016277

    Abstract The prognosis of patients with human epidermal growth factor receptor-2 (HER2)-overexpressed metastatic breast cancer (MBC) has improved drastically following the development of anti-HER2 therapies. We question what factors are involved in the improved outcome by the treatment. One hundred and two MBC patients who received chemotherapy were classified into groups according to breast cancer subtype: luminal/HER2-negative (n = 50), HER2 (n = 26), and triple-negative subtypes (n = 26). Clinicopathologic features and clinical outcomes of the groups were compared. Disease-free intervals in the triple-negative group were significantly shorter than those in the other two groups.… More >

Displaying 1-10 on page 1 of 3. Per Page